IL6 and COVID-19: Most patients under IL-6 inhibition show clinical improvement of symptoms such as hypoxia and changes in computed tomography (CT) opacity immediately after treatment, suggesting that this could be an efficient therapy for the treatment of COVID-19 with decreased 28-day all-cause mortality (33).